AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8986520 — intervention group
Group type: EXPERIMENTAL
Intervention: Photograph of chocolate
Number of subjects: 0
Study 8986520 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual chocolate
Number of subjects: 0
Study 8986520 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 8489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 10 mg/m2
Number of subjects: 47
Study 8489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 12 mg/m2
Number of subjects: 47
Study 8489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 15 mg/m2
Number of subjects: 47
Study 8489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin in acute myelogenous leukemia
Number of subjects: 47
Study 8489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin in chronic myelogenous leukemia in blast crisis
Number of subjects: 47
Study 8489296 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin in patients with prior anthracycline therapy
Number of subjects: 47
Study 3813060 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of intramuscular morphine 30‐60 min before induction
Number of subjects: 81
Study 3813060 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/kg of IV fentanyl 10 min after skin incision
Number of subjects: 81
Study 3813060 — intervention group
Group type: COMPARATOR
Intervention: halothane
Number of subjects: 81
Study 3813060 — intervention group
Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 81
Study 3813060 — intervention group
Group type: COMPARATOR
Intervention: enflurane
Number of subjects: 81
Study 29948896 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperlipidic-hypoglycemic diet
Number of subjects: 10
Study 29948896 — intervention group
Group type: EXPERIMENTAL
Intervention: fasting longer than 12 hours
Number of subjects: 10
Study 29948896 — intervention group
Group type: EXPERIMENTAL
Intervention: fasting associated with intravenous heparin
Number of subjects: 10
Study 29126612 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 61
Study 29126612 — intervention group
Group type: COMPARATOR
Intervention: TIVA (Propofol)
Number of subjects: 61
Study 27567897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT)
Number of subjects: 13
Study 27567897 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 13
Study 25093868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hochuekkito (oral) for 24 weeks
Number of subjects: 18
Study 25093868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Hochuekkito) for 24 weeks
Number of subjects: 18
Study 22382523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (CMG) treated with Chinese herbs for supplementing qi, nourishing yin and activating blood circulation, besides Western medicine treatment.
Number of subjects: 100
Study 22382523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (CMG)
Number of subjects: 100
Study 22382523 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (WMG)
Number of subjects: 100
Study 20669671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Medicine internal-external combined therapy (ipratropium bromide aerosol, ambroxol hydrochloride, Chinese recipe, acupoint sticking with Xiaochuan Plaster)
Number of subjects: 178
Study 20669671 — intervention group
Group type: COMPARATOR
Intervention: Atrovent Metered Dose Inhalation, oral Mucosolvan, Bailing Capsule, acupoint sticking with dummy plaster (Control)
Number of subjects: 178
Study 18772061 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 2986
Study 18772061 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 2986
Study 15944842 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved metabolic control (optimisation period for 6-12 months)
Number of subjects: 44
Study 15944842 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors (for two years)
Number of subjects: 44
Study 15944842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of improved metabolic control and ACE inhibitor therapy
Number of subjects: 44
Study 12638108 — intervention group
Group type: EXPERIMENTAL
Intervention: PREHAB program
Number of subjects: 94
Study 10189970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity long-term follow-up protocol (case monitoring) for alcohol abusers
Number of subjects: 0
Study 10189970 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 8898511 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) exercise at 65% VO2max for 30 minutes
Number of subjects: 8
Study 8898511 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity (MI) exercise at approximately 55% VO2max
Number of subjects: 8
Study 8898511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity (LI) exercise at approximately 45% VO2max
Number of subjects: 8
Study 8898511 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HI, MI, and LI
Number of subjects: 8
Study 1829388 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 37
Study 1829388 — intervention group
Group type: COMPARATOR
Intervention: Reconstructive surgery
Number of subjects: 37
Study 6294433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (opiate receptor blockade)
Number of subjects: 0
Study 30382806 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking+supplement
Number of subjects: 4
Study 30382806 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 4
Study 30382806 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity activity with complex cognitive demands (dancing)
Number of subjects: 4
Study 30382806 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 4
Study 26748734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 192
Study 26748734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 192
Study 26748734 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg
Number of subjects: 192
Study 26748734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg and 750 mg
Number of subjects: 192
Study 25811246 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating bracket system (3M SmartClip™)
Number of subjects: 138
Study 25811246 — intervention group
Group type: COMPARATOR
Intervention: Conventional bracket system (3M Victory™)
Number of subjects: 138
Study 24891576 — intervention group
Group type: COMPARATOR
Intervention: No drainage (group A)
Number of subjects: 575
Study 24891576 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage with ABT drain for six hours (group B)
Number of subjects: 575
Study 24891576 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage with ABT drain for 24 hours (group C)
Number of subjects: 575
Study 24891576 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including transfused patients)
Number of subjects: 575
Study 24891576 — intervention group
Group type: EXPERIMENTAL
Intervention: THR patients
Number of subjects: 575
Study 24891576 — intervention group
Group type: EXPERIMENTAL
Intervention: TKR patients
Number of subjects: 575
Study 21497935 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 60
Study 21497935 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with HbA(1c) < 7.0% (53 mmol/mol)
Number of subjects: 60
Study 21497935 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 19017418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12)
Number of subjects: 256
Study 19017418 — intervention group
Group type: COMPARATOR
Intervention: Diet/Placebo
Number of subjects: 256
Study 19017418 — intervention group
Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 256
Study 17351155 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid for 10 days combined with a low-calorie diet
Number of subjects: 32
Study 17351155 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet only (control group)
Number of subjects: 32
Study 17351155 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat group
Number of subjects: 32
Study 17351155 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32
Study 15068431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Tenon infiltration with 3 mL of bupivacaine 0.50%
Number of subjects: 100
Study 15068431 — intervention group
Group type: COMPARATOR
Intervention: Classical analgesic drugs (control group)
Number of subjects: 100
Study 11399986 — intervention group
Group type: EXPERIMENTAL
Intervention: Information/motivation program with free distribution of female and male condoms
Number of subjects: 1929
Study 11399986 — intervention group
Group type: COMPARATOR
Intervention: Male condoms and related information (control)
Number of subjects: 1929
Study 9442428 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (fish oil: 30% n-3 PUFA)
Number of subjects: 37
Study 9442428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil containing only 1% of n-3 PUFA)
Number of subjects: 37
Study 7835813 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdomino-pelvic radiation therapy (APRT)
Number of subjects: 0
Study 7835813 — intervention group
Group type: COMPARATOR
Intervention: 32P
Number of subjects: 0
Study 2822723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 20
Study 2822723 — intervention group
Group type: COMPARATOR
Intervention: Albumin (Control)
Number of subjects: 20
Study 31925268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane general anesthesia
Number of subjects: 12
Study 31925268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-plus-ketamine general anesthesia
Number of subjects: 12
Study 29441841 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion with standard care
Number of subjects: 0
Study 29441841 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 27276742 — intervention group
Group type: COMPARATOR
Intervention: Moringa Oleifera (MO) leaf at 0 g
Number of subjects: 10
Study 27276742 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera (MO) leaf at 1 g
Number of subjects: 10
Study 27276742 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera (MO) leaf at 2 g
Number of subjects: 10
Study 27276742 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa Oleifera (MO) leaf at 4 g
Number of subjects: 10
Study 27276742 — intervention group
Group type: COMPARATOR
Intervention: Moringa Oleifera (MO) leaf at 4 g vs baseline (0 g)
Number of subjects: 10
Study 24364856 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distancing
Number of subjects: 3
Study 24364856 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinterpretation
Number of subjects: 3
Study 24364856 — intervention group
Group type: COMPARATOR
Intervention: No-regulation control
Number of subjects: 3
Study 22664649 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention with trained lay coaches promoting asthma management strategies
Number of subjects: 120
Study 22664649 — intervention group
Group type: EXPERIMENTAL
Intervention: More coach contacts overall
Number of subjects: 120
Study 22664649 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable models adjusting for characteristics of participants and coaching process
Number of subjects: 120
Study 20379731 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 95
Study 20379731 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 95
Study 18536623 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered concomitantly with pneumococcal conjugate vaccine
Number of subjects: 0
Study 18536623 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine administered separately
Number of subjects: 0
Study 15813838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole for 2 weeks)
Number of subjects: 20
Study 15813838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Number of subjects: 20
Study 15813838 — intervention group
Group type: COMPARATOR
Intervention: No-antibiotics group
Number of subjects: 20
Study 12551964 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 degrees step increments of visual feedback rotation, every 45 trials (up to a total of 90 degrees)
Number of subjects: 0
Study 12551964 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 degrees rotation from the onset of exposure
Number of subjects: 0
Study 12551964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual distortion
Number of subjects: 0
Study 12551964 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the distortion
Number of subjects: 0
Study 10395431 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chiropractic spinal manipulation (SMT)
Number of subjects: 22
Study 10395431 — intervention group
Group type: COMPARATOR
Intervention: Placebo chiropractic spinal manipulation (sham SMT)
Number of subjects: 22
Study 8893580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autologous donation (IAD)
Number of subjects: 90
Study 8893580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IAD)
Number of subjects: 90
Study 2068243 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 420
Study 2068243 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccine
Number of subjects: 420
Study 6661383 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 0
Study 6661383 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.50 mg
Number of subjects: 0
Study 6661383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31102142 — intervention group
Group type: EXPERIMENTAL
Intervention: BVDV infection in ICC
Number of subjects: 0
Study 31102142 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real-time PCR (qRT-PCR) validation of DEGs
Number of subjects: 0
Study 29950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 7.5 mg intravenous dose
Number of subjects: 20
Study 29950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar device
Number of subjects: 20
Study 29950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 20
Study 29950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 20
Study 29950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbarbed sutures
Number of subjects: 20
Study 29950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer instrument activation times
Number of subjects: 20
Study 27651039 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 50
Study 27651039 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 50
Study 24577124 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10, 15, or 20 mg once daily
Number of subjects: 42
Study 24577124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 or 150 mg twice daily
Number of subjects: 42
Study 24577124 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Dabigatran
Number of subjects: 42
Study 22686551 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT)
Number of subjects: 14
Study 22686551 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive-behavioral therapy (CBT)
Number of subjects: 14
Study 20082712 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline in combination with 6% dextran‐70 (HSD)
Number of subjects: 65
Study 20082712 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 65
Study 20082712 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 healthy subjects)
Number of subjects: 65
Study 17565563 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (BAI)
Number of subjects: 987
Study 17565563 — intervention group
Group type: COMPARATOR
Intervention: Control group with screening and assessment
Number of subjects: 987
Study 17565563 — intervention group
Group type: COMPARATOR
Intervention: Control group with screening only
Number of subjects: 987
Study 17565563 — intervention group
Group type: COMPARATOR
Intervention: All groups (BAI and controls)
Number of subjects: 987
Study 15632210 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of intracellular SH2D1A protein using four-color flow cytometry in patients with XLP
Number of subjects: 15
Study 15632210 — intervention group
Group type: COMPARATOR
Intervention: Detection of intracellular SH2D1A protein in carriers of SH2D1A mutations
Number of subjects: 15
Study 15632210 — intervention group
Group type: COMPARATOR
Intervention: Detection of intracellular SH2D1A protein in males with clinical syndromes consistent with XLP
Number of subjects: 15
Study 12668373 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 48277
Study 12668373 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antidepressants
Number of subjects: 48277
Study 12668373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48277
Study 10659559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp dissection
Number of subjects: 94
Study 10659559 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 94
Study 8754401 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treated patients (12 patients, HD for 138 +/- 66 months)
Number of subjects: 26
Study 8754401 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients, HD for 121 +/- 35 months)
Number of subjects: 26
Study 8754401 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO group
Number of subjects: 26
Study 8754401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 1985006 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of domperidone
Number of subjects: 20
Study 1985006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6831839 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% ethanol (v/v in saline)
Number of subjects: 5
Study 6831839 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (400 micrograms by aerosol)
Number of subjects: 5
Study 30954363 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRITION
Number of subjects: 81
Study 30954363 — intervention group
Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 81
Study 29691288 — intervention group
Group type: COMPARATOR
Intervention: Prehypertension
Number of subjects: 29439
Study 29691288 — intervention group
Group type: COMPARATOR
Intervention: Stage 1 Hypertension
Number of subjects: 29439
Study 29691288 — intervention group
Group type: COMPARATOR
Intervention: Stage 2 Hypertension
Number of subjects: 29439
Study 29691288 — intervention group
Group type: COMPARATOR
Intervention: Stage 3 Hypertension
Number of subjects: 29439
Study 29691288 — intervention group
Group type: COMPARATOR
Intervention: Rise in BP from normotension to hypertension
Number of subjects: 29439
Study 29691288 — intervention group
Group type: COMPARATOR
Intervention: Rise in BP from prehypertension to hypertension
Number of subjects: 29439
Study 26011050 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 80
Study 23240939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% acemannan in Carbopol® 934P NF
Number of subjects: 180
Study 23240939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide
Number of subjects: 180
Study 23240939 — intervention group
Group type: COMPARATOR
Intervention: pure Carbopol® 934P NF
Number of subjects: 180
Study 20650490 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy (SWL) using Compact Delta II lithotriptor
Number of subjects: 100
Study 18959683 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 168
Study 18959683 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 168
Study 17586832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation with single embryo transfer (n = 197)
Number of subjects: 253
Study 17586832 — intervention group
Group type: COMPARATOR
Intervention: Standard GnRH agonist long-protocol ovarian stimulation with double embryo transfer (n = 194)
Number of subjects: 253
Study 12940501 — intervention group
Group type: EXPERIMENTAL
Intervention: Told-yes smokers (could smoke)
Number of subjects: 0
Study 12940501 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with 15 s delay
Number of subjects: 0
Study 12940501 — intervention group
Group type: COMPARATOR
Intervention: Smokers with 60 s delay
Number of subjects: 0
Study 11107744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan with autologous stem cell support
Number of subjects: 274
Study 8818844 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg tablets with food
Number of subjects: 3
Study 8818844 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg suspension with food
Number of subjects: 3
Study 8818844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg sachet with food
Number of subjects: 3
Study 8818844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg sachet (absolute bioavailability)
Number of subjects: 3
Study 1468240 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac SR 600 mg daily
Number of subjects: 30
Study 1468240 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac SR 1200 mg daily
Number of subjects: 30
Study 1468240 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 30
Study 6204142 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (200 mmol)
Number of subjects: 201
Study 6204142 — intervention group
Group type: COMPARATOR
Intervention: Reduced sodium intake (70 mmol)
Number of subjects: 201